Tuberculosis (TB) Differential Diagnoses (original) (raw)

Diagnostic Considerations

Tuberculosis (TB) is well known for its ability to masquerade as other infectious and disease processes. For example, congenital TB can mimic congenital syphilis or cytomegalovirus (CMV) infection. Along with the differentials listed in the next section, conditions with a presentation that may resemble pulmonary TB include the following:

Conditions to be included in the differential diagnosis of extrapulmonary TB include the following:

Dermatologic differential diagnosis:

Diagnosis of skin infection with M tuberculosis involves the following:

Differential Diagnoses

eMedicine Logo

  1. Tuberculosis. https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Available athttps://www.who.int/news-room/fact-sheets/detail/tuberculosis. April 21, 2023; Accessed: September 25, 2023.
  2. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007 Aug 15. 196 Suppl 1:S86-107. [QxMD MEDLINE Link].
  3. Moreira J, Fochesatto JB, Moreira AL, Pereira M, Porto N, Hochhegger B. Tuberculous pneumonia: a study of 59 microbiologically confirmed cases. J Bras Pneumol. 2011 Mar-Apr. 1. [QxMD MEDLINE Link].[Full Text].
  4. John Bernardo, MD. Epidemiology and pathology of miliary and extrapulmonary tuberculosis. Available athttps://medilib.ir/uptodate/show/8029. Sep 2023.; Accessed: Nov, 2023.
  5. Nyamathi A, Salem BE, Shin SS, Jones AA, Garfin DR, Yadav K, et al. Effect of a Nurse-Led Community Health Worker Intervention on Latent Tuberculosis Medication Completion Among Homeless Adults. Nurs Res. 2021 Nov-Dec 01. 2-3. [QxMD MEDLINE Link].[Full Text].
  6. Guzman K, Crowder R, Leddy A, Maraba N, Jennings L, Ahmed S, et al. Acceptability and feasibility of digital adherence technologies for drug-susceptible tuberculosis treatment supervision: A meta-analysis of implementation feedback. PLOS Digit Health. 2023 Aug 15. [QxMD MEDLINE Link].[Full Text].
  7. Roguin A. Rene Theophile Hyacinthe Laënnec (1781-1826): the man behind the stethoscope. Clin Med Res. 2006 Sep. [QxMD MEDLINE Link].[Full Text].
  8. Tubiana M. [Wilhelm Conrad Röntgen and the discovery of X-rays]. Bull Acad Natl Med. 1996 Jan. 180 (1):97-108. [QxMD MEDLINE Link].
  9. Trends in Tuberculosis, 2021. https://www.cdc.gov/tb/publications/factsheets/statistics/tbtrends.htm. Available athttps://www.cdc.gov/tb/publications/factsheets/statistics/tbtrends.htm. November 9, 2022; Accessed: 10/03/2023.
  10. Tuberculosis and HIV. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/treatment/tuberculosis-hiv. Available athttps://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/treatment/tuberculosis-hiv. 2023; Accessed: 9/29/2023.
  11. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City--turning the tide. N Engl J Med. 1995 Jul 27. 333 (4):229-33. [QxMD MEDLINE Link].
  12. Myra A. Montalbano Carol M. Knowles Deborah A. Adams Patsy A. Hall Robert F. Fagan Karl A. Brendel Harry R. Holden Gerald F. Jones Division of Public Health Surveillance and Informatics Epidemiology Program Office. Summary of Notifiable Diseases, United States 1996. MMWR. Ocr 31, 1997. Available at https://www.cdc.gov/mmwr/preview/mmwrhtml/00050719.htm.
  13. Ritacco V, Di Lonardo M, Reniero A, Ambroggi M, Barrera L, Dambrosi A, et al. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis. 1997 Sep. 176 (3):637-42. [QxMD MEDLINE Link].
  14. From the Centers for Disease Control and Prevention. Tuberculosis treatment interruptions--Ivanovo Oblast, Russian Federation, 1999. JAMA. 2001 Apr 18. 285 (15):1953-4. [QxMD MEDLINE Link].
  15. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989 Mar 2. 320 (9):545-50. [QxMD MEDLINE Link].
  16. WHO. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. World Health Organization. Available athttps://www.who.int/tb/challenges/mdr/tdrfaqs/en/index.html. December 15, 2022; Accessed: July 5, 2023.
  17. Raviglione MC. Tuberculosis. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. eds. Harrison's Principles of Internal Medicine, 20e. McGraw Hill; 2018. McGraw Hill.; [Full Text].
  18. Mlambo CK, Warren RM, Poswa X, Victor TC, Duse AG, Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis. 2008 Jan. 12(1):99-104. [QxMD MEDLINE Link].
  19. Global Tuberculosis Programme. Global tuberculosis report 2020. October 14, 2020. Available at https://www.who.int/publications/i/item/9789240013131.
  20. Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF,et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob Health. 2020 Sep. 8 (9):e1132-e1141. [QxMD MEDLINE Link].
  21. Global Tuberculosis Programme. Global tuberculosis report 2020. 14 October 2020. Available at https://www.who.int/publications/i/item/9789240013131.
  22. CDC. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. MMWR Recomm Rep. 2009 Feb 13. 58:1-43. [QxMD MEDLINE Link].
  23. Sokolove PE, Lee BS, Krawczyk JA, et al. Implementation of an emergency department triage procedure for the detection and isolation of patients with active pulmonary tuberculosis. Ann Emerg Med. 2000 Apr. 35(4):327-36. [QxMD MEDLINE Link].
  24. Moran GJ, McCabe F, Morgan MT, Talan DA. Delayed recognition and infection control for tuberculosis patients in the emergency department. Ann Emerg Med. 1995 Sep. 26(3):290-5. [QxMD MEDLINE Link].
  25. Menzies D, Joshi R, Pai M. Risk of tuberculosis infection and disease associated with work in health care settings. Int J Tuberc Lung Dis. 2007 Jun. 11(6):593-605. [QxMD MEDLINE Link].
  26. Brehm TT, Terhalle E. [Extrapulmonary tuberculosis]. Dtsch Med Wochenschr. 2023 Sep. 148 (19):1242-1249. [QxMD MEDLINE Link].
  27. Chen Q, Chen W, Hao F. Cutaneous tuberculosis: A great imitator. Clin Dermatol. 2019 May-Jun. 37 (3):192-199. [QxMD MEDLINE Link].
  28. Bates B, Crowell EL. Ophthalmic manifestations of tuberculosis. Curr Opin Ophthalmol. 2023 Nov 1. 34 (6):529-534. [QxMD MEDLINE Link].
  29. Patel SS, Saraiya NV, Tessler HH, Goldstein DA. Mycobacterial ocular inflammation: delay in diagnosis and other factors impacting morbidity. JAMA Ophthalmol. 2013 Jun. 131 (6):752-8. [QxMD MEDLINE Link].
  30. WHO. Leading health agencies outline updated terminology for pathogens that transmit through the air. World Health Organization. Available athttps://www.who.int/news/item/18-04-2024-leading-health-agencies-outline-updated-terminology-for-pathogens-that-transmit-through-the-air. April 18, 2024; Accessed: April 25, 2024.
  31. Pfyffer, G. E. 2007. Mycobacterium: general characteristics, laboratory detection, and staining procedures. P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC; 1: 543-572.
  32. Daniel W. Fitzgerald, Timothy R. Sterling and David W. Haas. Mycobacterium tuberculosis. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th. Elsevier; June 6, 2021. 2985-3021. [Full Text].
  33. Russell DG. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunol Rev. 2011 Mar. 240 (1):252-68. [QxMD MEDLINE Link].
  34. Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, Takatsu K, et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med. 2008 Jan 21. 205 (1):105-15. [QxMD MEDLINE Link].
  35. Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol. 2012 Apr 20. 12 (5):352-66. [QxMD MEDLINE Link].
  36. Pagán AJ, Ramakrishnan L. Immunity and Immunopathology in the Tuberculous Granuloma. Cold Spring Harb Perspect Med. 2014 Nov 6. 5 (9):[QxMD MEDLINE Link].
  37. Lenaerts A, Barry CE 3rd, Dartois V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev. 2015 Mar. 264 (1):288-307. [QxMD MEDLINE Link].
  38. Mattila JT, Ojo OO, Kepka-Lenhart D, Marino S, Kim JH, Eum SY, et al. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol. 2013 Jul 15. 191 (2):773-84. [QxMD MEDLINE Link].
  39. Lin PL, Ford CB, Coleman MT, Myers AJ, Gawande R, Ioerger T, et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med. 2014 Jan. 20 (1):75-9. [QxMD MEDLINE Link].
  40. Lin PL, Flynn JL. The End of the Binary Era: Revisiting the Spectrum of Tuberculosis. J Immunol. 2018 Nov 1. 201 (9):2541-2548. [QxMD MEDLINE Link].
  41. Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science. 2010 Jan 22. 327 (5964):466-9. [QxMD MEDLINE Link].
  42. Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy HA, et al. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis. 1999 Mar. 179 (3):637-45. [QxMD MEDLINE Link].
  43. Sheen P, O'Kane CM, Chaudhary K, Tovar M, Santillan C, Sosa J, et al. High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation. Eur Respir J. 2009 Jan. 33 (1):134-41. [QxMD MEDLINE Link].
  44. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, et al. Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog. 2008 Nov. 4 (11):e1000204. [QxMD MEDLINE Link].
  45. Singh V, Jamwal S, Jain R, Verma P, Gokhale R, Rao KV. Mycobacterium tuberculosis-driven targeted recalibration of macrophage lipid homeostasis promotes the foamy phenotype. Cell Host Microbe. 2012 Nov 15. 12 (5):669-81. [QxMD MEDLINE Link].
  46. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol. 2009 Sep. 10 (9):943-8. [QxMD MEDLINE Link].
  47. Davis JM, Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell. 2009 Jan 9. 136 (1):37-49. [QxMD MEDLINE Link].
  48. Schreiber HA, Harding JS, Hunt O, Altamirano CJ, Hulseberg PD, Stewart D, et al. Inflammatory dendritic cells migrate in and out of transplanted chronic mycobacterial granulomas in mice. J Clin Invest. 2011 Oct. 121 (10):3902-13. [QxMD MEDLINE Link].
  49. Elkington PT, Ugarte-Gil CA, Friedland JS. Matrix metalloproteinases in tuberculosis. Eur Respir J. 2011 Aug. 38 (2):456-64. [QxMD MEDLINE Link].
  50. Palaci M, Dietze R, Hadad DJ, Ribeiro FK, Peres RL, Vinhas SA, et al. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol. 2007 Dec. 45 (12):4064-6. [QxMD MEDLINE Link].
  51. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis. 1965 Nov. 92 (5):687-703. [QxMD MEDLINE Link].
  52. Coleman MT, Chen RY, Lee M, Lin PL, Dodd LE, Maiello P, et al. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med. 2014 Dec 3. 6 (265):265ra167. [QxMD MEDLINE Link].
  53. Prosser G, Brandenburg J, Reiling N, Barry CE 3rd, Wilkinson RJ, Wilkinson KA. The bacillary and macrophage response to hypoxia in tuberculosis and the consequences for T cell antigen recognition. Microbes Infect. 2017 Mar. 19 (3):177-192. [QxMD MEDLINE Link].
  54. Simmons JD, Stein CM, Seshadri C, Campo M, Alter G, Fortune S, et al. Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. Nat Rev Immunol. 2018 Sep. 18 (9):575-589. [QxMD MEDLINE Link].
  55. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012 Jan. 12 (1):45-55. [QxMD MEDLINE Link].
  56. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Primers. 2016 Oct 27. 2:16076. [QxMD MEDLINE Link].
  57. Abrahams KA, Besra GS. Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target. Parasitology. 2018 Feb. 145 (2):116-133. [QxMD MEDLINE Link].
  58. Verhagen LM, van den Hof S, van Deutekom H, et al. Mycobacterial factors relevant for transmission of tuberculosis. J Infect Dis. 2011 May. 203(9):1249-55. [QxMD MEDLINE Link].
  59. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11. 345(15):1098-104. [QxMD MEDLINE Link].
  60. Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled Corticosteroids and Risk of Tuberculosis in Patients with Respiratory Diseases. Am J Respir Crit Care Med. 2010 Oct 1. [QxMD MEDLINE Link].
  61. Aravindan PP. Host genetics and tuberculosis: Theory of genetic polymorphism and tuberculosis. Lung India. 2019 May-Jun. 36 (3):244-252. [QxMD MEDLINE Link].
  62. Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med. 1998 Mar 5. 338(10):640-4. [QxMD MEDLINE Link].
  63. Cervino AC, Lakiss S, Sow O, Hill AV. Allelic association between the NRAMP1 gene and susceptibility to tuberculosis in Guinea-Conakry. Ann Hum Genet. 2000 Nov. 64:507-12. [QxMD MEDLINE Link].
  64. Searle S, Blackwell JM. Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious disease susceptibility. J Med Genet. 1999 Apr. 36(4):295-9. [QxMD MEDLINE Link].[Full Text].
  65. Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med. 1998 Mar 5. 338 (10):640-4. [QxMD MEDLINE Link].
  66. Shaw MA, Collins A, Peacock CS, Miller EN, Black GF, Sibthorpe D, et al. Evidence that genetic susceptibility to Mycobacterium tuberculosis in a Brazilian population is under oligogenic control: linkage study of the candidate genes NRAMP1 and TNFA. Tuber Lung Dis. 1997. 78 (1):35-45. [QxMD MEDLINE Link].
  67. Druszczyńska M, Strapagiel D, Kwiatkowska S, Kowalewicz-Kulbat M, Rózalska B, Chmiela M, et al. Tuberculosis bacilli still posing a threat. Polymorphism of genes regulating anti-mycobacterial properties of macrophages. Pol J Microbiol. 2006. 55 (1):7-12. [QxMD MEDLINE Link].
  68. Saunders BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol. 2007 Feb-Mar. 85 (2):103-11. [QxMD MEDLINE Link].
  69. Nadesalingam J, Dodds AW, Reid KB, Palaniyar N. Mannose-binding lectin recognizes peptidoglycan via the N-acetyl glucosamine moiety, and inhibits ligand-induced proinflammatory effect and promotes chemokine production by macrophages. J Immunol. 2005 Aug 1. 175 (3):1785-94. [QxMD MEDLINE Link].
  70. LeBouder E, Rey-Nores JE, Rushmere NK, Grigorov M, Lawn SD, Affolter M, et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol. 2003 Dec 15. 171 (12):6680-9. [QxMD MEDLINE Link].
  71. Intemann CD, Thye T, Niemann S, et al. Autophagy gene variant IRGM -261T contributes to protection from tuberculosis caused by Mycobacterium tuberculosis but not by M. africanum strains. PLoS Pathog. 2009 Sep. 5(9):e1000577. [QxMD MEDLINE Link].[Full Text].
  72. King KY, Lew JD, Ha NP, Lin JS, Ma X, Graviss EA, et al. Polymorphic allele of human IRGM1 is associated with susceptibility to tuberculosis in African Americans. PLoS One. 2011 Jan 21. 6 (1):e16317. [QxMD MEDLINE Link].
  73. Chan J, Flynn J. The immunological aspects of latency in tuberculosis. Clin Immunol. 2004 Jan. 110 (1):2-12. [QxMD MEDLINE Link].
  74. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun. 2002 Aug. 70 (8):4501-9. [QxMD MEDLINE Link].
  75. Rossouw M, Nel HJ, Cooke GS, van Helden PD, Hoal EG. Association between tuberculosis and a polymorphic NFkappaB binding site in the interferon gamma gene. Lancet. 2003 May 31. 361(9372):1871-2. [QxMD MEDLINE Link].
  76. Levin M, Newport MJ, D'Souza S, et al. Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene?. Lancet. 1995 Jan 14. 345(8942):79-83. [QxMD MEDLINE Link].
  77. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med. 1996 Dec 26. 335(26):1941-9. [QxMD MEDLINE Link].
  78. Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet. 2007 Apr. 39 (4):523-8. [QxMD MEDLINE Link].
  79. Barreiro LB, Neyrolles O, Babb CL, et al. Promoter variation in the DC-SIGN-encoding gene CD209 is associated with tuberculosis. PLoS Med. 2006 Feb. 3(2):e20. [QxMD MEDLINE Link].[Full Text].
  80. Tuberculosis-Data and Statistics. www.cdc.gov. Available athttps://www.cdc.gov/tb/statistics/default.htm. 03/23/2023; Accessed: 10/25/2023.
  81. WHO. Tuberculosis. World Health Organization. Available athttps://www.who.int/news-room/fact-sheets/detail/tuberculosis. October 29, 2024; Accessed: October 30, 2024.
  82. Reported TB in the US, 2021 Surveillance Report. https://www.cdc.gov/tb/statistics/reports/2021/demographics.htm. Available athttps://www.cdc.gov/tb/statistics/reports/2021/demographics.htm. November 29, 2022; Accessed: 10/25/2023.
  83. Cox HS, Morrow M, Deutschmann PW. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ. 2008 Mar 1. 336(7642):484-7. [QxMD MEDLINE Link].[Full Text].
  84. Jasmer RM, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection?. Am J Respir Crit Care Med. 2004 Dec 15. 170(12):1360-6. [QxMD MEDLINE Link].
  85. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med. 1999 Oct 14. 341(16):1174-9. [QxMD MEDLINE Link].
  86. Waitt CJ, Peter K Banda N, White SA, et al. Early deaths during tuberculosis treatment are associated with depressed innate responses, bacterial infection, and tuberculosis progression. J Infect Dis. 2011 Aug. 204(3):358-62. [QxMD MEDLINE Link].[Full Text].
  87. Yoo SD, Cattamanchi A, Den Boon S, Worodria W, Kisembo H, Huang L, et al. Clinical significance of normal chest radiographs among HIV-seropositive patients with suspected tuberculosis in Uganda. Respirology. 2011 Jul. 16 (5):836-41. [QxMD MEDLINE Link].
  88. Palmieri F, Girardi E, Pellicelli AM, Rianda A, Bordi E, Rizzi EB, et al. Pulmonary tuberculosis in HIV-infected patients presenting with normal chest radiograph and negative sputum smear. Infection. 2002 Apr. 30 (2):68-74. [QxMD MEDLINE Link].
  89. Sossen B, Richards AS, Heinsohn T, Frascella B, Balzarini F, Oradini-Alacreu A, et al. The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis. Lancet Respir Med. 2023 Apr. 11 (4):367-379. [QxMD MEDLINE Link].
  90. ROPER WH, WARING JJ. Primary serofibrinous pleural effusion in military personnel. Am Rev Tuberc. 1955 May. 71 (5):616-34. [QxMD MEDLINE Link].
  91. BIEHL JP. Miliary tuberculosis; a review of sixty-eight adult patients admitted to a municipal general hospital. Am Rev Tuberc. 1958 Apr. 77 (4):605-22. [QxMD MEDLINE Link].
  92. Maartens G, Willcox PA, Benatar SR. Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. Am J Med. 1990 Sep. 89 (3):291-6. [QxMD MEDLINE Link].
  93. Roth BJ. Searching for tuberculosis in the pleural space. Chest. 1999 Jul. 116 (1):3-5. [QxMD MEDLINE Link].
  94. Diacon AH, Van de Wal BW, Wyser C, Smedema JP, Bezuidenhout J, Bolliger CT, et al. Diagnostic tools in tuberculous pleurisy: a direct comparative study. Eur Respir J. 2003 Oct. 22 (4):589-91. [QxMD MEDLINE Link].
  95. Garg RK, Malhotra HS, Gupta R. Spinal cord involvement in tuberculous meningitis. Spinal Cord. 2015 Sep. 53 (9):649-57. [QxMD MEDLINE Link].
  96. Erdem H, Ozturk-Engin D, Tireli H, Kilicoglu G,et al. Hamsi scoring in the prediction of unfavorable outcomes from tuberculous meningitis: results of Haydarpasa-II study. J Neurol. 2015. 262 (4):890-8. [QxMD MEDLINE Link].
  97. Linares LF, Valcarcel A, Mesa Del Castillo J, Saiz E, Bermudez A, Castellon P. Tuberculous arthritis with multiple joint involvement. J Rheumatol. 1991 Apr. 18 (4):635-6. [QxMD MEDLINE Link].
  98. Saltzman SJ, Feigin RD. Tuberculous otitis media and mastoiditis. J Pediatr. 1971 Dec. 79 (6):1004-6. [QxMD MEDLINE Link].
  99. Bruschini L, Ciabotti A, Berrettini S. Chronic Tuberculous Otomastoiditis: A Case Report. J Int Adv Otol. 2016 Aug. 12 (2):219-221. [QxMD MEDLINE Link].
  100. Sebastian SK, Singhal A, Sharma A, Doloi P. Tuberculous otitis media -series of 10 cases. J Otol. 2020 Sep. 15 (3):95-98. [QxMD MEDLINE Link].
  101. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005 Dec 16. 54:49-55. [QxMD MEDLINE Link].
  102. Ang M, Htoon HM, Chee SP. Diagnosis of tuberculous uveitis: clinical application of an interferon-gamma release assay. Ophthalmology. 2009 Jul. 116(7):1391-6. [QxMD MEDLINE Link].
  103. Schuurmans MM, Ellmann A, Bouma H, Diacon AH, Dyckmans K, Bolliger CT. Solitary pulmonary nodule evaluation with 99mTc-methoxy isobutyl isonitrile in a tuberculosis-endemic area. Eur Respir J. 2007 Dec. 30(6):1090-5. [QxMD MEDLINE Link].
  104. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005 Jan 15. 191(2):150-8. [QxMD MEDLINE Link].
  105. Muga R, Ferreros I, Langohr K, et al. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS. 2007 Nov 30. 21(18):2521-7. [QxMD MEDLINE Link].
  106. Sterling TR, Lau B, Zhang J, et al. Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. J Infect Dis. 2011 Sep. 204(6):893-901. [QxMD MEDLINE Link].[Full Text].
  107. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis. 2010 Oct 1. 51(7):823-9. [QxMD MEDLINE Link].
  108. [Guideline] Jensen PA, Lambert LA, Iademarco MF, Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005 Dec 30. 54:1-141. [QxMD MEDLINE Link].
  109. Brown M, Varia H, Bassett P, Davidson RN, Wall R, Pasvol G. Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate. Clin Infect Dis. 2007 Jun 1. 44(11):1415-20. [QxMD MEDLINE Link].
  110. Jafari C, Thijsen S, Sotgiu G, et al. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. Am J Respir Crit Care Med. 2009 Oct 1. 180(7):666-73. [QxMD MEDLINE Link].[Full Text].
  111. Tan SH, Tan BH, Goh CL, et al. Detection of Mycobacterium tuberculosis DNA using polymerase chain reaction in cutaneous tuberculosis and tuberculids. Int J Dermatol. 1999 Feb. 38(2):122-7. [QxMD MEDLINE Link].
  112. Vieites B, Suarez-Penaranda JM, Perez Del Molino ML, et al. Recovery of Mycobacterium tuberculosis DNA in biopsies of erythema induratum--results in a series of patients using an improved polymerase chain reaction technique. Br J Dermatol. 2005 Jun. 152(6):1394-6. [QxMD MEDLINE Link].
  113. [Guideline] Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep. 2009 Jan 16. 58(1):7-10. [QxMD MEDLINE Link].
  114. Reuters Health Information. Direct nucleic acid amplification testing improves TB diagnosis. Medscape Medical News. June 6, 2013. [Full Text].
  115. Marks SM, Cronin W, Venkatappa T, et al. The Health-System Benefits and Cost-effectiveness of Using Mycobacterium Tuberculosis Direct Nucleic Acid Amplification Testing to Diagnose Tuberculosis Disease in the United States. Clin Infect Dis. 2013 May 22. [QxMD MEDLINE Link].
  116. Badak FZ, Kiska DL, Setterquist S, et al. Comparison of mycobacteria growth indicator tube with BACTEC 460 for detection and recovery of mycobacteria from clinical specimens. J Clin Microbiol. 1996 Sep. 34(9):2236-9. [QxMD MEDLINE Link].[Full Text].
  117. Choi JH, Lee KW, Kang HR, et al. Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. Chest. 2010 Feb. 137(2):393-400. [QxMD MEDLINE Link].
  118. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010 Sep 9. 363(11):1005-15. [QxMD MEDLINE Link].[Full Text].
  119. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011 Apr 30. 377(9776):1495-505. [QxMD MEDLINE Link].
  120. Minion J, Leung E, Menzies D, Pai M. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2010 Oct. 10(10):688-98. [QxMD MEDLINE Link].
  121. CDC. Classification of Tuberculin Skin Reactions. Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/tb/publications/LTBI/diagnosis.htm#3. Accessed: July 5, 2023.
  122. [Guideline] Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010 Jun 25. 59:1-25. [QxMD MEDLINE Link].
  123. Manuel O, Humar A, Preiksaitis J, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant. 2007 Dec. 7(12):2797-801. [QxMD MEDLINE Link].
  124. Mazurek GH, Weis SE, Moonan PK, et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis. 2007 Oct 1. 45(7):837-45. [QxMD MEDLINE Link].
  125. Chang KC, Leung CC. Systematic review of interferon-gamma release assays in tuberculosis: focus on likelihood ratios. Thorax. 2010 Mar. 65(3):271-6. [QxMD MEDLINE Link].
  126. Leung CC, Yam WC, Yew WW, et al. T-Spot.TB outperforms tuberculin skin test in predicting tuberculosis disease. Am J Respir Crit Care Med. 2010 Sep 15. 182(6):834-40. [QxMD MEDLINE Link].
  127. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon-? release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med. 2011 Jan 1. 183(1):88-95. [QxMD MEDLINE Link].
  128. Kim SH, Lee SO, Park JB, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant. 2011 Sep. 11(9):1927-35. [QxMD MEDLINE Link].
  129. Donald PR, Schaaf HS, Gie RP, Beyers N, Sirgel FA, Venter A. Stool microscopy and culture to assist the diagnosis of pulmonary tuberculosis in childhood. J Trop Pediatr. 1996 Oct. 42 (5):311-2. [QxMD MEDLINE Link].
  130. MacLean E, Sulis G, Denkinger CM, Johnston JC, Pai M, Ahmad Khan F. Diagnostic Accuracy of Stool Xpert MTB/RIF for Detection of Pulmonary Tuberculosis in Children: a Systematic Review and Meta-analysis. J Clin Microbiol. 2019 Jun. 57 (6):[QxMD MEDLINE Link].
  131. Kokuto H, Sasaki Y, Yoshimatsu S, Mizuno K, Yi L, Mitarai S. Detection of Mycobacterium tuberculosis (MTB) in Fecal Specimens From Adults Diagnosed With Pulmonary Tuberculosis Using the Xpert MTB/Rifampicin Test. Open Forum Infect Dis. 2015 Apr. 2 (2):ofv074. [QxMD MEDLINE Link].
  132. [Guideline] Treatment of tuberculosis. MMWR Recomm Rep. 2003 Jun 20. 52:1-77. [QxMD MEDLINE Link].
  133. Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L et sl. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemp Clin Trials. 2020 Mar. 90:105938. [QxMD MEDLINE Link].
  134. Lin HC, Lin HC, Chen SF. Increased risk of low birthweight and small for gestational age infants among women with tuberculosis. BJOG. 2010 Apr. 117(5):585-90. [QxMD MEDLINE Link].
  135. Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med. 2010 Apr 1. 181(7):743-51. [QxMD MEDLINE Link].
  136. CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. CDC. Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/tb/TB_HIV_Drugs/default.htm. Accessed: 07/05/2023.
  137. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010 Feb 25. 362(8):697-706. [QxMD MEDLINE Link].[Full Text].
  138. Torok ME, Farrar JJ. When to start antiretroviral therapy in HIV-associated tuberculosis. N Engl J Med. 2011 Oct 20. 365(16):1538-40. [QxMD MEDLINE Link].
  139. Donovan J, Bang ND, Imran D, Nghia HDT, Burhan E, Huong DTT et al. Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults. N Engl J Med. 2023 Oct 12. 389 (15):1357-1367. [QxMD MEDLINE Link].
  140. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2018. 2019. [Full Text].
  141. Kurbatova EV, Cavanaugh JS, Dalton T, Click E, Cegielski JP. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009. Clin Infect Dis. 2013 Jul 9. [QxMD MEDLINE Link].
  142. Boggs W. Increasing Prevalence of Pyrazinamide-Resistant Tuberculosis. Medscape [serial online]. Available athttps://www.medscape.com/viewarticle/808192. Accessed: July 29, 2013.
  143. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019 Nov 15. 200 (10):e93-e142. [QxMD MEDLINE Link].
  144. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019. [Full Text].
  145. Sirturo (bedaquiline) prescribing information [package insert]. Titusville, NJ: Janssen Therapeutics, Division of Johnson & Johnson. December, 2012. Available at [Full Text].
  146. Tucker ME. FDA approves bedaquiline for resistant TB treatment. Medscape Medical News. Dec 31, 2012. Medscape. Available athttps://www.medscape.com/viewarticle/776901. Accessed: July 5, 2023.
  147. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009 Jun 4. 360(23):2397-405. [QxMD MEDLINE Link].
  148. Achar J, Hewison C, Cavalheiro AP, Skrahina A, Cajazeiro J, Nargiza P, et al. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis. Emerg Infect Dis. 2017 Oct. 23 (10):1711-1713. [QxMD MEDLINE Link].[Full Text].
  149. CDC. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep. 2013 Oct 25. 62:1-12. [QxMD MEDLINE Link].
  150. Barclay L. MDR TB: CDC Issues Guidelines for Use of New Drug. Medscape [serial online]. Available athttps://www.medscape.com/viewarticle/813151. Accessed: July 5, 2023.
  151. Conradie F, Diacon AH, Everitt D, Mendel C, van Niekerk C, Howell P, et al. The NIX-TB trial of pretomanid, bedaquiline and linezolid to treat XDR TB. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2017. Seattle, Washington. February 15, 2017. [Full Text].
  152. Pretomanid [package insert]. Hyderabad, India: Mylan (for TB Alliance). August, 2019. Available at [Full Text].
  153. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011 Dec 8. 365(23):2155-66. [QxMD MEDLINE Link].
  154. Sanofi Receives FDA Approval of Priftin® (Rifapentine) Tablets for the Treatment of Latent Tuberculosis Infection. Available athttps://en.sanofi.com/Images/37707_20141202_priftin_en.pdf. Accessed: Dec 10 2014.
  155. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000 Jun 9. 49:1-51. [QxMD MEDLINE Link].
  156. Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, et al. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection. MMWR Morb Mortal Wkly Rep. 2018 Jun 29. 67 (25):723-726. [QxMD MEDLINE Link].
  157. Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, et al. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017 Nov 7. [QxMD MEDLINE Link].
  158. CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR. 2011;60:1650-1653.
  159. Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2011 Jan 8. 377(9760):147-52. [QxMD MEDLINE Link].
  160. Weir RE, Gorak-Stolinska P, Floyd S, et al. Persistence of the immune response induced by BCG vaccination. BMC Infect Dis. 2008 Jan 25. 8:9. [QxMD MEDLINE Link].[Full Text].
  161. Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature. 2020 Jan. 577 (7788):95-102. [QxMD MEDLINE Link].
  162. Ayieko J, Abuogi L, Simchowitz B, Bukusi EA, Smith AH, Reingold A. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. BMC Infect Dis. 2014 Feb 20. 14:91. [QxMD MEDLINE Link].[Full Text].
  163. [Guideline] Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020 Feb 14. 69 (1):1-11. [QxMD MEDLINE Link].
  164. Hackethal V. Short TB Therapies Fail in Larger, Longer Trials. Medscape Medical News. Available athttps://www.medscape.com/viewarticle/833799. Accessed: July 5, 2023.
  165. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014 Oct 23. 371(17):1588-98. [QxMD MEDLINE Link].
  166. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014 Oct 23. 371(17):1599-608. [QxMD MEDLINE Link].
  167. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014 Oct 23. 371(17):1577-87. [QxMD MEDLINE Link].
  168. Warner DF, Mizrahi V. Shortening treatment for tuberculosis--to basics. N Engl J Med. 2014 Oct 23. 371(17):1642-3. [QxMD MEDLINE Link].
  169. Nardell EA. Mycobacteria. Porter RE.The Merck Manual of Diagnosis and Therapy. Rahway, NJ: Merck & Co Inc; Reviewed/Revised July 2022. [Full Text].
  170. Chakinala RC, Khatri AM. Gastrointestinal Tuberculosis. StatPearls. 2024 Jan. [QxMD MEDLINE Link].[Full Text].
  171. Menzies D, Adjobimey M, Ruslami R, et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med. 2018 Aug 2. 379 (5):440-453. [QxMD MEDLINE Link].
  172. Diallo T, Adjobimey M, Ruslami R, et al. Safety and Side Effects of Rifampin versus Isoniazid in Children. N Engl J Med. 2018 Aug 2. 379 (5):454-463. [QxMD MEDLINE Link].
  173. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006 Aug 1. 174(3):331-8. [QxMD MEDLINE Link].
  174. World Health Organization. Antituberculosis drug resistance in the world. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance WHO. Geneva. 2008. 1-120. [Full Text].
  175. CDC. CDC. Trends in Tuberculosis – United States, 2011. Centers for Disease Control and Prevention. Available athttps://www.cdc.gov/mmwr/preview/mmwrhtml/mm6111a2.htm?s_cid=mm6111a2_w. Accessed: July 5, 2023.
  176. Leung CC, Lam TH, Chan WM, et al. Lower risk of tuberculosis in obesity. Arch Intern Med. 2007 Jun 25. 167(12):1297-304. [QxMD MEDLINE Link].
  177. Slama K, Chiang CY, Enarson DA, et al. Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J Tuberc Lung Dis. 2007 Oct. 11(10):1049-61. [QxMD MEDLINE Link].
  178. Tosh K, Campbell SJ, Fielding K, et al. Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa. Proc Natl Acad Sci U S A. 2006 Jul 5. 103(27):10364-8. [QxMD MEDLINE Link].[Full Text].
  179. Khor CC, Vannberg FO, Chapman SJ, et al. CISH and susceptibility to infectious diseases. N Engl J Med. 2010 Jun 3. 362(22):2092-101. [QxMD MEDLINE Link].
  180. Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet. 2007 Apr. 39(4):523-8. [QxMD MEDLINE Link].[Full Text].
  181. CDC. Tuberculosis (TB). Data and Statistics. Available athttps://www.cdc.gov/tb/statistics/default.htm. March 23, 2023; Accessed: July 5, 2023.
  182. WHO. Global tuberulosis control 2008: surveillance, planning, financing. World Health Organization. Available athttps://www.who.int/topics/tuberculosis/en/. Accessed: July 5, 2023.
  183. Xu P, Chen H, Xu J, Wu M, Zhu X, Wang F, et al. Moxifloxacin is an effective and safe candidate agent for the tuberculosis treatment: a meta-analysis. Int J Infect Dis. 2015 Oct 16. [QxMD MEDLINE Link].
  184. History of World TB Day. https://www.cdc.gov/tb/worldtbday/history.htm. Available athttps://www.cdc.gov/tb/worldtbday/history.htm. February 15, 2023; Accessed: September 25, 2023.
  185. Patterson B, Morrow C, Singh V, Moosa A, Gqada M, Woodward J, et al. Detection of Mycobacterium tuberculosis bacilli in bio-aerosols from untreated TB patients. Gates Open Res. 2017. 1:11. [QxMD MEDLINE Link].[Full Text].
  186. Lin PL, Ford CB, Coleman MT, Myers AJ, Gawande R, Ioerger T, et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med. 2014 Jan. 20 (1):75-9. [QxMD MEDLINE Link].
  187. Irwin SM, Prideaux B, Lyon ER, Zimmerman MD, Brooks EJ, Schrupp CA, et al. Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice. ACS Infect Dis. 2016 Apr 8. 2 (4):251-267. [QxMD MEDLINE Link].
  188. Barberis I, Bragazzi NL, Galluzzo L, Martini M. The history of tuberculosis: from the first historical records to the isolation of Koch's bacillus. J Prev Med Hyg. 2017 Mar. 58 (1):E9-E12. [QxMD MEDLINE Link].
  189. Epstein DM, Kline LR, Albelda SM, Miller WT. Tuberculous pleural effusions. Chest. 1987 Jan. 91 (1):106-9. [QxMD MEDLINE Link].
  190. Mukwenha S, Dzinamarira T, Mugurungi O, Musuka G. Maintaining robust HIV and tuberculosis services in the COVID-19 era: A public health dilemma in Zimbabwe. Int J Infect Dis. 2020 Nov. 100:394-395. [QxMD MEDLINE Link].
  191. Global Tuberculosis Programme. Global tuberculosis report 2021. Available at https://www.who.int/publications/i/item/9789240037021.
  192. Moro ML, Gori A, Errante I, Infuso A, Franzetti F, Sodano L, et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS. 1998 Jun 18. 12 (9):1095-102. [QxMD MEDLINE Link].

Author

Coauthor(s)

Nelson Ivan Agudelo Higuita, MD, DTM&H, CTH® Edith Kinney Gaylor Presidential Professor, Associate Professor, Program Director, Infectious Diseases Fellowship Program, Medical Director, Refugee and Travel Clinic, Department of Medicine, Section of Infectious Diseases, University of Oklahoma Health Sciences Center; Attending Physician, Infectious Diseases Consultation Service, Department of General Internal Medicine, Oklahoma University Medical Center

Nelson Ivan Agudelo Higuita, MD, DTM&H, CTH® is a member of the following medical societies: Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Maria Alkozah, MD, MPH Assistant Professor of Medicine, University of Oklahoma College of Medicine; Faculty, Section of Infectious Diseases, Department of Medicine, Medical Director for Antimicrobial Stewardship, Medical Director for the Outpatient Antimicrobial Therapy Program, University of Oklahoma Medical Center

Maria Alkozah, MD, MPH is a member of the following medical societies: American College of Preventive Medicine, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Additional Contributors

Acknowledgements

Erica Bang State University of New York Downstate Medical Center College of Medicine

Disclosure: Nothing to disclose.

Diana Brainard, MD Consulting Staff, Department of Infectious Disease, Massachusetts General Hospital

Disclosure: Nothing to disclose.

Pamela S Chavis, MD Professor, Department of Ophthalmology and Neurosciences, Medical University of South Carolina College of Medicine

Pamela S Chavis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Ophthalmology, and North American Neuro-Ophthalmology Society

Disclosure: Nothing to disclose.

Dirk M Elston, MD Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Theodore J Gaeta, DO, MPH, FACEP Clinical Associate Professor, Department of Emergency Medicine, Weill Cornell Medical College; Vice Chairman and Program Director of Emergency Medicine Residency Program, Department of Emergency Medicine, New York Methodist Hospital; Academic Chair, Adjunct Professor, Department of Emergency Medicine, St George's University School of Medicine

Theodore J Gaeta, DO, MPH, FACEP is a member of the following medical societies: Alliance for Clinical Education, American College of Emergency Physicians, Clerkship Directors in Emergency Medicine, Council of Emergency Medicine Residency Directors, New York Academy of Medicine, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Aaron Glatt, MD Professor of Clinical Medicine, New York Medical College; President and CEO, Former Chief Medical Officer, Departments of Medicine and Infectious Diseases, St Joseph Hospital (formerly New Island Hospital)

Aaron Glatt, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physician Executives, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Infectious Diseases Society of America, International AIDS Society, and SocietyforHealthcareEpidemiology of America

Disclosure: Nothing to disclose.

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

John M Leedom, MD Professor Emeritus of Medicine, Keck School of Medicine of the University of Southern California

John M Leedom, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Society for Microbiology, Infectious Diseases Society of America, International AIDS Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

James Li, MD Former Assistant Professor, Division of Emergency Medicine, Harvard Medical School; Board of Directors, Remote Medicine

Disclosure: Nothing to disclose.

Jeffrey Meffert, MD Assistant Clinical Professor of Dermatology, University of Texas School of Medicine at San Antonio

Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, and Texas Dermatological Society

Disclosure: Nothing to disclose.

Monte S Meltzer, MD Chief, Dermatology Service, Union Memorial Hospital

Monte S Meltzer, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Susannah K Mistr, MD Resident Physician, Department of Ophthalmology, University of Maryland Medical Center

Susannah K Mistr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, American Medical Association, American Medical Student Association/Foundation, American Society of Cataract and Refractive Surgery, and South Carolina Medical Association

Disclosure: Nothing to disclose.

Carol A Nacy, PhD Adjunct Professor, Department of Biology, Catholic University of America; Adjunct Professor, Department of Tropical Medicine and Microbiology, George Washington University

Carol A Nacy, PhD is a member of the following medical societies: American Academy of Microbiology and American Society for Microbiology

Disclosure: Sequella, Inc. Ownership interest Employment; Sequella, Inc. Ownership interest investor

J James Rowsey, MD Former Director of Corneal Services, St Luke's Cataract and Laser Institute

J James Rowsey, MD is a member of the following medical societies: American Academy of Ophthalmology, American Association for the Advancement of Science, American Medical Association, Association for Research in Vision and Ophthalmology, Florida Medical Association, Pan-American Association of Ophthalmology, Sigma Xi, and Southern Medical Association

Disclosure: Nothing to disclose.

Hampton Roy Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

John D Sheppard Jr, MD, MMSc Professor of Ophthalmology, Microbiology and Molecular Biology, Clinical Director, Thomas R Lee Center for Ocular Pharmacology, Ophthalmology Residency Research Program Director, Eastern Virginia Medical School; President, Virginia Eye Consultants

John D Sheppard Jr, MD, MMSc is a member of the following medical societies: American Academy of Ophthalmology, American Society for Microbiology, American Society of Cataract and Refractive Surgery, American Uveitis Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Richard H Sinert, DO Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Richard H Sinert, DO is a member of the following medical societies: American College of Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Keith Tsang, MD Resident Physician, Clinical Assistant Instructor, Department of Emergency Medicine, State University of New York Downstate, Kings County Hospital

Keith Tsang, MD is a member of the following medical societies: American College of Emergency Physicians, Emergency Medicine Residents Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Shyam Verma, MBBS, DVD, FAAD Clinical Associate Professor, Department of Dermatology, University of Virginia; Adjunct Associate Professor, Department of Dermatology, State University of New York at Stonybrook, Adjunct Associate Professor, Department of Dermatology, University of Pennsylvania

Shyam Verma, MBBS, DVD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association

Disclosure: Nothing to disclose.

Eric L Weiss, MD, DTM&H Medical Director, Office of Service Continuity and Disaster Planning, Fellowship Director, Stanford University Medical Center Disaster Medicine Fellowship, Chairman, SUMC and LPCH Bioterrorism and Emergency Preparedness Task Force, Clinical Associate Progressor, Department of Surgery (Emergency Medicine), Stanford University Medical Center

Eric L Weiss, MD, DTM&H is a member of the following medical societies: American College of Emergency Physicians, American College of Occupational and Environmental Medicine, American Medical Association, American Society of Tropical Medicine and Hygiene, Physicians for Social Responsibility, Southeastern Surgical Congress, Southern Association for Oncology, Southern Clinical Neurological Society, and Wilderness Medical Society

Disclosure: Nothing to disclose.